Invokana Lawsuit: Plaintiffs Reveal Potentially Dangerous DKA Side Effects Of Drug Following The FDA Safety Warning

April 25, 2016 – – TheProductLawyers.com comments on multiple lawsuits recently filed against Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation) implicating their new-generation, type-2 diabetes drug, Invokana. This drug was the first of a group of similar drugs approved to treat diabetes which are known as SGLT2 class inhibitors. FDA adverse event reports suggest that there may be other potential litigants who have allegedly been harmed by the drug. It is reported that patients who have taken Invokana allege that using the drug directly led to the development of the life-threatening condition, diabetic ketoacidosis. Similar allegations have been raised by all of the plaintiffs involved in each of these recent Invokana litigations.

Diabetic ketoacidosis is a deadly condition which occurs when the patient’s bloodstream retains a surplus of toxic acids which should have been eliminated from the body by a functional renal system. It has been noted to develop in as little as 24-hours and can result in comatose states or fatality if it remains untreated and undiagnosed.

One of the first lawsuits filed in the U.S. against Invokana manufacturers took place on December 15th, 2015. The complaint was filed in the U.S. District Court for the Southern District of Alabama under case number 1:15-cv-00636. Detailed court documents state that this particular plaintiff involved began to take Invokana in December of 2014, and stopped shortly thereafter due to the sudden development of diabetic ketoacidosis.

An alarmingly similar lawsuit was filed just days before this one, on December 10th, 2015. The suit is filed under case number 15-12-00653 in the Court of Common Pleas in Philadelphia, Pennsylvania. Details disclosed in this suit allege after only 3 months of use the plaintiff discontinued use of the drug due to the development of diabetic ketoacidosis.

The U.S. Food and Drug Administration recently released a safety communication potentially linking Invokana use to the development of diabetic ketoacidosis. The FDA has also required Invokana manufacturer Janssen to make accurate adjustments to the drug’s warning label to sufficiently alert patients to the risk of diabetic ketoacidosis as well as urinary tract infections. The agency has warned those taking the drug to watch for any signs of the development of diabetic ketoacidosis. Warning symptoms include nausea and vomiting, trouble breathing, excess fatigue, and abdominal pain.

For more information about the Invokana lawsuits, or this press release, please contact TheProductLawyers.com on 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60009509